Bacterial protein secretion platform for efficient peptide production
This innovative bacterial protein expression system enables the efficient production of high-purity peptides via fermentation. By secreting proteins in a single step, it reduces purification costs and enhances process efficiency, particularly for complex repeating peptides.
Overview
The bacterial protein secretion platform developed by Opera Bioscience revolutionizes peptide production through an efficient fermentation process. Utilizing a unique bacterial host capable of secreting proteins in a single step, this technology significantly reduces purification costs and process time. The platform is especially effective for peptides with repeating sequences, such as spider silk, providing high purity levels and reducing tech transfer risks.
Technical specifications
Key features:
- Single-step secretion: Achieves up to 80% purity before downstream processing, reducing the need for extensive purification.
- Versatile application: Successfully expresses and secretes over 90% of tested proteins, accommodating a wide range of peptides.
- Enhanced efficiency: Capable of expressing peptides as longer chains of tandem repeats (1-6x), which are then cleaved into individual sequences, optimizing fermentation output.
- Custom cleavage methods: Develops specific protease methods to separate tandem repeat chains without leaving residual scarring, ensuring high-quality peptide products.
Technology readiness level
Currently at TRL 4, this platform has demonstrated successful expression and secretion in a laboratory setting. Future phases will focus on optimizing expression and purification methods, scaling up the process, and establishing a full benchtop production system within 12 months.
About Opera Bioscience
Opera Bioscience is a biotechnology startup that has developed a proprietary bacterial protein secretion platform designed to make the manufacturing of recombinant proteins and growth factors more efficient, scalable, and cost-effective. By utilizing the type III secretion system of Salmonella enterica typhimurium, the platform enables the transport of proteins from the cytoplasm to the extracellular space in a single step. This approach simplifies the production process by eliminating the need for cell lysis and complex downstream purification steps, resulting in high-purity proteins. The technology is capable of producing soluble, active enzymes, antibody fragments, and antimicrobial peptides, positioning it for use across various applications including therapeutics, regenerative medicine, and the cultivated meat industry.
For customers and partners, Opera Bioscience addresses the high cost and complexity associated with traditional recombinant protein manufacturing. By offering a platform that reduces recovery costs and enables continuous manufacturing, the company aims to broaden access to essential biological materials for research, clinical applications, and sustainable consumer goods. Founded in 2021 and based in Evanston, Illinois, the company has received support from the National Science Foundation through multiple SBIR awards to optimize its strain development and scale its manufacturing processes. Opera continues to work on commercializing its platform, focusing on meeting industry demands for high-quality, affordable proteins and growth factors.
Inquire about this partnering listing
Industry applications
delivered to your inbox.